UPDATE 1-Pfizer says US court nixes Celebrex patent; generics loom

March 12 (Reuters) - A U.S. court shot down a patent covering Pfizer Inc's blockbuster Celebrex painkiller, the drugmaker said, giving generic rivals an earlier U.S. entry that analysts estimated could cost the company $3 billion in revenue by the end of 2015.